Olivier Alexis Georges Querolle

This inventor holds 33 USPTO granted patents and 13 published patent applications, plus 15 CIPO patents and 24 EPO patents, primarily in Cancer Therapeutics. Top assignees: Janssen Pharmaceutica Nv, Astex Therapeutics Limited. Active years: 2016-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Olivier Alexis Georges Querolle. Retrieved from https://idiyas.com/inventor/olivier-alexis-georges-querolle

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 33 (Patent Applications = 13)

% Patents Active = 97.0

CIPO Patents = 15 (Patent Applications = 16)

EPO Patents = 24 (Patent Applications = 34)

Average Co-Inventor Count = 7.6

ph-index = 10

Forward Citations = 246(Granted Patents)

Location History:

Val de Reuil, FR (2016)
Evreux, FR (2016 - 2019)
Issy-les Moulineaux, FR (2021 - 2022)
Vigor, FR (2022)
Saint Vigor, FR (2016 - 2024)

Company Filing History:

21 out of 2,101

Janssen Pharmaceutica Nv

patents

12 out of 126

Astex Therapeutics Limited

patents

Years Active: 2016-2025

Loading Chart...

Areas of Expertise:

Spiro Derivatives

NIK Inhibitors

PI3K-beta Inhibitors

FGFR Kinase

Heteroaromatic Derivatives

Quinoxaline

Bicyclic Inhibitors

Azepane Inhibitors

Cancer Treatment

Pyrazolyl Compounds

Benzodiazepines

33 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12473295 - SUBSTITUTED STRAIGHT CHAIN SPIRO DERIVATIVES (2025-11-18),

2. 12084462 - Spiro bicyclic inhibitors of menin-MLL interaction (2024-09-10),

3. 11542247 - Bi-heteroaryl substitute 1,4-benzodiazepines and uses thereof for the treatment of cancer (2023-01-03),

4. 11530226 - Azepane inhibitors of menin-MLL interaction (2022-12-20),

5. 11396517 - Exo-aza spiro inhibitors of menin-MLL interaction (2022-07-26),

6. 11267804 - (R)-8-(1-((3-fluorophenyl)amino)ethyl)-N-(2-hydroxyethyl)-2-morpholinoquinoxaline-6-carboxamide for inhibiting phosphoinositide-3-kinase activity (2022-03-08),

7. 11236084 - Substituted azaindoline derivatives as NIK inhibitors (2022-02-01),

8. 11220517 - Spiro bicyclic inhibitors of menin-MLL interaction (2022-01-11),

9. 11186589 - Cyanoindoline derivatives as NIK inhibitors (2021-11-30),

10. 11180487 - Substituted cyanoindoline derivatives as NIK inhibitors (2021-11-23),

11. 11155555 - Compounds (2021-10-26),

12. 11136311 - Heteroaromatic derivatives as NIK inhibitors (2021-10-05),

13. 11130751 - Quinoxaline and pyridopyrazine derivatives as PI3K-beta inhibitors (2021-09-28),

14. 11001569 - 6-membered heteroaromatic substituted cyanoindoline derivatives as NIK inhibitors (2021-05-11),

15. 10975100 - Fused bicyclic inhibitors of menin-MLL interaction (2021-04-13),

Title: The Innovative Mind of Olivier Alexis Georges Querolle

Introduction: Olivier Alexis Georges Querolle, a talented inventor hailing from Saint Vigor, France, is known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Olivier Alexis Georges Querolle has recently been granted patents for his cutting-edge inventions in the fields of renewable energy and sustainable transportation.

Career Highlights: Throughout his illustrious career, Olivier Alexis Georges Querolle has consistently pushed the boundaries of technological advancement. His work has not only revolutionized existing industries but has also paved the way for new and exciting developments in the field.

Collaborations: Olivier Alexis Georges Querolle has collaborated with leading research institutions, universities, and innovative companies to bring his ideas to life. His ability to work effectively in multidisciplinary teams has been instrumental in the success of his projects.

Conclusion: Olivier Alexis Georges Querolle stands as a shining example of innovation and creativity in the world of inventors. His passion for pushing the limits of what is possible continues to inspire others in the industry to strive for greatness.

Profile summary based on public USPTO records.